## Lynn Zechiedrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7435922/publications.pdf

Version: 2024-02-01

51	2,430	218677  26  h-index	48
papers	citations		g-index
60	60	60	3141 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Advances in Non-Viral DNA Vectors for Gene Therapy. Genes, 2017, 8, 65.	2.4	279
2	Expression of Multidrug Efflux Pump Genes <i>acrAB-tolC</i> , <i>mdfA</i> , and <i>norE</i> in <i>Escherichia coli</i> Clinical Isolates as a Function of Fluoroquinolone and Multidrug Resistance. Antimicrobial Agents and Chemotherapy, 2011, 55, 921-924.	3.2	165
3	The why and how of DNA unlinking. Nucleic Acids Research, 2009, 37, 661-671.	14.5	164
4	Mechanisms Accounting for Fluoroquinolone Resistance in <i>Escherichia coli</i> Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2009, 53, 235-241.	3.2	141
5	Quorum sensing and multidrug transporters in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2386-2391.	7.1	127
6	Structural diversity of supercoiled DNA. Nature Communications, 2015, 6, 8440.	12.8	122
7	DNA Disentangling by Type-2 Topoisomerases. Journal of Molecular Biology, 2004, 340, 933-939.	4.2	102
8	Topoisomerase IV, alone, unknots DNA in E. coli. Genes and Development, 2001, 15, 748-761.	5.9	92
9	Bullied no more: when and how DNA shoves proteins around. Quarterly Reviews of Biophysics, 2012, 45, 257-299.	5.7	75
10	Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2009, 53, 229-234.	3.2	69
11	Temporal Interplay between Efflux Pumps and Target Mutations in Development of Antibiotic Resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2012, 56, 1680-1685.	3.2	68
12	In the absence of writhe, DNA relieves torsional stress with localized, sequence-dependent structural failure to preserve B-form. Nucleic Acids Research, 2009, 37, 5568-5577.	14.5	61
13	Contributions of the Combined Effects of Topoisomerase Mutations toward Fluoroquinolone Resistance in <i>Escherichia coli</i> i> Antimicrobial Agents and Chemotherapy, 2007, 51, 4205-4208.	3.2	60
14	Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infectious Diseases, 2008, 8, 4.	2.9	58
15	Supercoiled Minivector DNA resists shear forces associated with gene therapy delivery. Gene Therapy, 2012, 19, 94-100.	4.5	57
16	Exploring writhe in supercoiled minicircle DNA. Journal of Physics Condensed Matter, 2006, 18, S145-S159.	1.8	56
17	Topological Information Embodied in Local Juxtaposition Geometry Provides a Statistical Mechanical Basis for Unknotting by Type-2 DNA Topoisomerases. Journal of Molecular Biology, 2006, 361, 268-285.	4.2	56
18	A role for topoisomerase III in a recombination pathway alternative to RuvABC. Molecular Microbiology, 2005, 58, 80-101.	2.5	55

#	Article	IF	CITATIONS
19	Hin-mediated DNA knotting and recombining promote replicon dysfunction and mutation. BMC Molecular Biology, 2007, 8, 44.	3.0	55
20	Effects of Circular DNA Length on Transfection Efficiency by Electroporation into HeLa Cells. PLoS ONE, 2016, 11, e0167537.	2.5	53
21	Toward Repurposing Ciclopirox as an Antibiotic against Drug-Resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS ONE, 2013, 8, e69646.	2.5	51
22	Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells. Gene Therapy, 2011, 18, 220-224.	4.5	49
23	TopA, the Sulfolobus solfataricus topoisomerase III, is a decatenase. Nucleic Acids Research, 2018, 46, 861-872.	14.5	39
24	Inferring Global Topology from Local Juxtaposition Geometry: Interlinking Polymer Rings and Ramifications for Topoisomerase Action. Biophysical Journal, 2006, 90, 2344-2355.	0.5	35
25	Wicked: The untold story of ciprofloxacin. PLoS Pathogens, 2018, 14, e1006805.	4.7	33
26	A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II. Antimicrobial Agents and Chemotherapy, 2004, 48, 4495-4504.	3.2	32
27	Influence of DNA sequence on the structure of minicircles under torsional stress. Nucleic Acids Research, 2017, 45, 7633-7642.	14.5	32
28	Action at Hooked or Twisted–Hooked DNA Juxtapositions Rationalizes Unlinking Preference of Type-2 Topoisomerases. Journal of Molecular Biology, 2010, 400, 963-982.	4.2	27
29	Emergence of Klebsiella pneumoniae ST273 Carrying blaNDM-7 and ST656 Carrying blaNDM-1 in Manila, Philippines. Microbial Drug Resistance, 2016, 22, 585-588.	2.0	26
30	Supercoiling and looping promote DNA base accessibility and coordination among distant sites. Nature Communications, 2021, 12, 5683.	12.8	24
31	Combining Random Gene Fission and Rational Gene Fusion To Discover Near-Infrared Fluorescent Protein Fragments That Report on Protein–Protein Interactions. ACS Synthetic Biology, 2015, 4, 615-624.	3.8	23
32	Prevalence of hypervirulent Klebsiella pneumoniae-associated genes rmpA and magA in two tertiary hospitals in Houston, TX, USA. Journal of Medical Microbiology, 2016, 65, 1047-1048.	1.8	21
33	Electrostatics of DNA–DNA juxtapositions: consequences for type II topoisomerase function. Journal of Physics Condensed Matter, 2006, 18, S173-S185.	1.8	18
34	A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine, 2021, 39, 1248-1256.	3.8	16
35	Local site preference rationalizes disentangling by DNA topoisomerases. Physical Review E, 2010, 81, 031902.	2.1	14
36	Novel Conserved Genotypes Correspond to Antibiotic Resistance Phenotypes of E. coli Clinical Isolates. PLoS ONE, 2013, 8, e65961.	2.5	10

#	Article	IF	CITATIONS
37	Differences Between Positively and Negatively Supercoiled DNA that Topoisomerases May Distinguish. The IMA Volumes in Mathematics and Its Applications, 2009, , 73-121.	0.5	9
38	Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli. PLoS ONE, 2019, 14, e0210547.	2.5	7
39	Improving therapeutic potential of non-viral minimized DNA vectors. Cell & Gene Therapy Insights, 2020, 6, 1489-1505.	0.1	7
40	Assessing Sensitivity to Antibacterial Topoisomerase II Inhibitors. Current Protocols in Pharmacology, 2007, 39, Unit3.13.	4.0	5
41	Topoisomerase IB-DNA Interactions: X Marks the Spot. Structure, 2010, 18, 661-663.	3.3	4
42	Escherichia coli DNA ligase B may mitigate damage from oxidative stress. PLoS ONE, 2017, 12, e0180800.	2.5	4
43	Repurposed Transcriptomic Data Reveal Small Viral RNA Produced by Influenza Virus during Infection in Mice. PLoS ONE, 2016, 11, e0165729.	2.5	4
44	Adult Memory T Cell Responses to the Respiratory Syncytial Virus Fusion Protein During a Single RSV Season (2018–2019). Frontiers in Immunology, 2022, 13, 823652.	4.8	4
45	Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine, 2022, 40, 536-543.	3.8	3
46	Importance of disentanglement and entanglement during DNA replication and segregation. Physics of Life Reviews, 2016, 18, 160-164.	2.8	2
47	Biophysics Meets Gene Therapy: How Exploring Supercoiling-Dependent Structural Changes in DNA Led to the Development of Minivector DNA. Technology and Innovation, 2019, 20, 427-439.	0.2	2
48	Editorial Comment to Genomeâ€wide transcriptome analysis of fluoroquinolone resistance in clinical isolates of <i>Escherichia coli</i> i>International Journal of Urology, 2012, 19, 368-369.	1.0	0
49	Comparing a Clinical Decision Tree vs. Standard of Care for Predicting ESBL+ Bacteremia in a VA Population. Open Forum Infectious Diseases, 2017, 4, S261-S261.	0.9	0
50	Discordant Ertapenem/Imipenem Susceptibilities in Enterobacter Bacteremia: Frequency and Outcomes. Open Forum Infectious Diseases, 2017, 4, S151-S152.	0.9	0
51	1822. Veterans Are Special: Clinical Decision Tree Misses ESBL Status in Bacteremic Veterans. Open Forum Infectious Diseases, 2018, 5, S518-S518.	0.9	0